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Abstract
Background: Valve-in-Valve (VIV) Transcatheter Aortic Valve Replacement (TAVR) is now the treatment of choice in
high-surgical-risk patients with failing aortic bioprosthesis. Although less performed, VIV-Transcatheter Mitral Valve
Replacement (TMVR) is a valid treatment option for selected high-risk patients with degenerated mitral bioprostheses.
Several cases of elective ViV- TAVR and -TMVR have been reported but only few were performed in critical
hemodynamic conditions.
Case presentation: We report the case of a patient underwent balloon-expandable transapical mitral valve-in-valve
implantation in an emergency setting due to a severe stenosis of a bioprosthesis in mitral position. The procedure was
successfully performed, with no residual mitral regurgitation or paravalvular leaks, and uneventful.
Conclusion: Transcatheter transapical mitral valve-in-valve implantation could represent a feasible and effective
strategy even in critical setting.
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Background
Valve-in-Valve (VIV) Transcatheter Aortic Valve Replace-
ment (TAVR) is now the treatment of choice in high-
surgical-risk patients with failing aortic bioprosthesis [1].
Although less performed, VIV-Transcatheter Mitral Valve
Replacement (TMVR) [2] represents a valid treatment
option for selected high-risk patients with degenerated
mitral bioprostheses. Several cases of elective ViV-
TAVR and -TMVR have been reported, but only a few
were performed in critical hemodynamic conditions, es-
pecially for dysfunctioning mitral bioprosthesis [3–5].
Over the last decade, the use of bioprosthesis or mitral
valve reconstruction, instead of mechanical valves, has
shown an important worldwide increase thanks to the
improved long-term results and inspired to the desire
of avoiding the need of life-long systemic anticoagula-
tion. The durability of bioprostheses, especially in mi-
tral position, can be very variable, depending on
patient’s and valve characteristics. Although surgical
redo operation is often possible, when there are no spe-
cific contraindications, it’s widely known that is accom-
panied by an increased mortality depending on age,
comorbidities and elective or urgent status of the proced-
ure. In this scenario, the incidence of failing surgical valves
in high surgical risk patients will surely increase. Even
more important is the choice of the right treatment option
in patients with critical conditions with high or
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unacceptable surgical risks. Usually stented bioprosthesis
present a progressive deterioration, evaluable with a
correct echocardiographic follow-up, permitting a
comfortable planning of the procedure but sometimes
patients could be admitted directly to the ER in
life-threating conditions without previous important
symptoms. We report the case of a patient underwent
balloon-expandable transapical mitral valve-in-valve
implantation in an emergency setting due to a severe
mitral stenosis of a surgical bioprosthesis.
Case presentation
An 82-year-old woman affected by hypertension, grade 1
obesity, severe chronic obstructive pulmonary disease
(COPD), atrial fibrillation (AF) and history of previous
cardiac surgery was admitted to the emergency room
(ER) for acute pulmonary edema and renal insufficiency.
Eight years before she underwent aortic and mitral valve
replacement (Magna Aortic 23 mm, Magna Mitral 27
mm – Edwards Lifescience, Irvine, CA, US), tricuspid
valve repair and atrial fibrillation radiofrequency ablation
complicated by complete AV-block and pacemaker im-
plantation. During the years she remained asymptomatic
without signs of heart failure. The trans-thoracic echo-
cardiography (TTE) performed at admission showed no
signs of endocarditis, no degeneration of the aortic bio-
prosthesis, good function of the repaired tricuspid valve
but a very severe mitral prosthesis stenosis (mean gradi-
ent 24 mmHg, PHT 420 msec, area 0,52 cm2; PAPS 66
mmHg) [Fig. 1; Additional file 1: Video 1]. ECG-gated
MDCT (multidetector computed tomography) recorded
no significant coronary artery disease, calcified thoracic
aorta, a calcified mitral bioprosthesis (outer-diameter
28.9mmx28.6 mm, inner-diameter 24.9 × 24.4 mm) and
bilateral severe pleural effusion. Laboratory testing
showed severe anemia. The patient was initially medic-
ally treated with endovenous diuretics, blood transfu-
sions, Continous Veno-Venous Hemofiltration (CVVH)
and bilateral pleural drainage. Despite medical therapy
optimization, the patient ‘s conditions remained critical
with hemodynamic instability, hypotension, initial neuro-
logical impairment and acute anuric renal failure. Evalu-
ated morbidity and mortality risk for surgical redo mitral
replacement (EuroSCORE II = 19,84; CHA2DS2-VASC
Score = 4; HAS BLED score = 4) our multidisciplinary
Heart-Team decided for an emergency ViV-TMVR in gen-
eral anesthesia with TEE-monitoring.
A temporary endocardial pacing leads was introduced
in the right ventricle through a 6-F sheath positioned
into the left femoral vein. Apex position was optimally
detected by TTE evaluation and the pericardium was
reached through a left anterolateral thoracotomy. As in
our standardized technique for transapical approach, we
proceed with the removal of all the adherence and with
the positioning of 2 perpendicular “U”-stitches (2/0
polypropylene - Prolene; Ethicon, Inc.), reinforced by
pledgets, directly on the myocardial tissue of the apex.
Performed the transapical puncture, we positioned a 7-F
sheath in order to introduce a 0.035 guide-wire through
the ventricle toward the mitral prosthesis reaching the
pulmonary vein. Over the guide-wire, we inserted a
MultiPurpose catheter to exchange the previous wire
with an ExtraStiff .035 in. (Cook Medical). The valve
delivery system was introduced through an expandable
21-F E-Sheath (Edwards Lifescience – Irvine, CA, US).
Under fluoroscopic and TEE guidance, we proceeded
with the deployment of a 29 mm Sapien-3 valve
(Edwards Lifescience – Irvine, CA, US) using the
Fig. 1 Preoperative transthoracic echocardiography showing severe mitral stenosis (transvalvular mean gradient 24 mmHg)
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annulus of the surgical bioprosthesis to recognize the
correct position (Fig. 2). There were no paravalvular
leaks or mitral regurgitation, and we immediately
observed a significant improvement in intraprocedural
monitoring parameter. The procedure was uneventful, as
well as ICU course (no needs of CVVH, inotropes or pro-
longed mechanical ventilation). The patient was dis-
charged 10 days after ViV-TMVR in good clinical
condition (NYHA class I-II). At pre-discharge TTE trans-
valvular mitral mean gradient was 3 mmHg, PAPS de-
creased to 29 mmHg and LV Ejection Fraction remained
55% Fig. 3, Additional file 2: Video 2, Additional file 3:
Video 3. At 1 month follow-up, the patient was asymp-
tomatic (NYHA class I-II) and the TTE confirmed the
absence of valve dysfunction or Paravalvular leak [Fig. 4].
Discussion and conclusions
Degeneration of surgically implanted bioprosthesis in
elderly patients is an increasing problem due to the
longer life-expectancy. Moreover, this issue is going to
interest also a younger population due to the growing
percentage of bioprosthesis implantation instead of the
Fig. 2 Valve-in-Valve implantation result
Fig. 3 PreDischarge Trans-Thoracic echocardiography Mitral prosthesis’ gradient
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mechanical ones. According to the current literature, the
perioperative risk of redo surgical intervention may
reach high percentage, up to 15% for redo aortic replace-
ment, depending on age, clinical conditions and comor-
bidities. To this increasing number of patients, we
should add the several situations in which surgery can’t
be performed because of technical contraindications
(porcelain aorta, really calcified mitral annulus, multiple
redos, frailty, etc.). We are in an era where TAVR is
already the therapy of choice for high-risk patients, and in
the next year, its indications are moving to the moderate-
risk ones. The valve-in-valve concept was developed by
Walther et al. in 2007 with the intent of decrease the reo-
perative risk in patients with a dysfunctional bioprosthesis.
ViV-TAVR is nowadays a standard procedure to treat eld-
erly patients with degenerated bioprosthesis, while mitral
valve-in-valve implantation is not yet so frequent probably
due to the difficulties of reaching the mitral with a periph-
eral approach. The need of a transapical puncture, as a
unique option, is probably going to end with the expand-
ing possibilities linked to transeptal system development.
Technically, the deployment of a transcatheter valve
into a surgically implanted bioprosthesis is a quite
simple procedure for skilled operators thanks to the
possibility to use the annulus of the surgical pros-
thesis as a reference point for the deployment of the
new one. Furthermore, using the degenerated valve
as a landing zone for the implantation assure a good
stability of the transcatheter prosthesis and it’s usually
not accompanied by significant paravalvular leaks.
Transapical approach requests high surgical skills, but
with the actual low-profile introducer sheaths the risk
of complications is minimized.
According to our experience, transapical valve-in-
valve transcatheter mitral implantation can be a
feasible and safe way to treat bioprosthesis dysfunc-
tion even in urgent and emergency settings, as we
have shown in this case.
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